GSK126 is a highly selective EZH2 inhibitor. It affects Rho/ROCK, Notch, and AMPK/PPAR-γ signaling by decreasing H3K27me3 levels to modulate epigenetic transcription, effectively inhibiting tumor proliferation and fibrosis, while promoting apoptosis.
GSK126 Mechanism of Action: EZH2 Inhibition in Tumor Cells Research
GSK126 MOA：Targeting EZH2/PRC2 Pathway for Oncology